论文信息 - High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. - 字舞流文

High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria.

P. Mclaughlin | R. Orlowski | L. Kwak | L. Fayad | S. Neelapu | M. Fanale | F. Hagemeister | J. Romaguera | F. Samaniego | N. Fowler | M. Wang | L. Lacerte